Why the study?
Increasing data indicate the VEGF family has potential in regulating lipids, but related studies are scant and concrete mechanisms remain to be examined for clinical application.
Key points are not available for this paper at this time.
Design
Review
The VEGF family shows potential in regulating lipid metabolism, offering a possible novel therapeutic target for dyslipidemia and metabolic diseases.
The vascular endothelial growth factor (VEGF) family plays a major role in tumors and ophthalmic diseases. However, increasingly more data reported its potential in regulating lipids. With its biological functions mainly expressed in lymphatic vessels, some factors in the families, like VEGF-A and VEGF-C, have been proved to regulate intestinal absorption of lipids by affecting chylous ducts. Other effects, including regulating lipoprotein lipase (LPL), endothelial lipase (EL), and recombinant syndecan 1 (SDC1), have also been confirmed. However, given the scant-related studies, further research should be conducted to examine the concrete mechanisms and provide pragmatic ways to apply them in the clinic. The VEGF family may treat dyslipidemia in specific ways that are different from common methods and concurrently contribute to the treatment of other metabolic diseases, like diabetes and obesity.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: